4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide | 64261-93-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide
• 英文别名: 4'-(2-Amino-1-hydroxyethyl)methanesulfonanilide；N-[4-(2-amino-1-hydroxyethyl)phenyl]methanesulfonamide
• CAS: 64261-93-4
• 化学式: C₉H₁₄N₂O₃S
• 分子量: 230.288
• InChiKey: QFNXQNYBIMKZLS-UHFFFAOYSA-N

物化性质

• 沸点：
  446.1±55.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-4-iodo-1H-pyridin-2-one 、 4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide 以 N,N-二甲基甲酰胺 为溶剂， 生成 (+/-)-N-(4-{1-hydroxy-2-[3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-2-oxo-1,2-dihydro-pyridin-4-ylamino]-ethyl}-phenyl)-methanesulfonamide
  参考文献：
  名称：

  Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

  摘要：

  A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.041
• 作为产物：
  描述：

  4-甲磺酰氨基苯甲醛 在 镍 咪唑 、 sodium hydroxide 、 四丁基氟化铵 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 生成 4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide
  参考文献：
  名称：

  Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

  摘要：

  A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.041

文献信息

• Antihypertensive sulfonanilides
  申请人：Burroughs Wellcome Co.

  公开号：US05102914A1

  公开（公告）日：1992-04-07

  The present invention is concerned with compounds of formula (I) ##STR1## wherein R.sub.1 is hydrogen; R.sub.2 is carbonyl; and R.sub.3 is hydroxy; and salts thereof, with processes for preparing same and with their use in medicine for the treatment of hypertension.

  本发明涉及化合物的公式(I) ##STR1## 其中R.sub.1为氢；R.sub.2为羰基；R.sub.3为羟基；及其盐，以及制备这些化合物的方法，以及它们在医学上用于治疗高血压的用途。
• Renin inhibitory peptides containing suleptanic acid or derivatives thereof
  申请人：THE UPJOHN COMPANY

  公开号：EP0355065A1

  公开（公告）日：1990-02-21

  The present invention provides novel renin-inhibiting peptides having a non-cleavable transition state insert corresponding to the 10,11- position of the renin substrate (angiotensinogen) and having a suleptanic acid moiety or derivatives thereof of the formula L₁ at the N-terminus of the peptide. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, other renin depen­dent cardiovascular disorders and ocular disorders. Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁

  本发明提供了一种新型的抑制肾素的肽，其具有对应于肾素底物（血管紧张素原）的10,11位的不可切割过渡态插入物，并在肽的N-末端具有苏力帕尼酸基团或其衍生物的L₁式。这种抑制剂对于诊断和控制肾素依赖性高血压、充血性心力衰竭、肾素依赖性高醛固酮症、其他肾素依赖性心血管疾病和眼部疾病非常有用。Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁
• Anti-hypertensive sulfonanilides
  申请人：Burroughs Wellcome Co.

  公开号：US05194450A1

  公开（公告）日：1993-03-16

  The present invention is concerned with compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen or C.sub.1-4 alkoxy; R.sub.2 is carbonyl, hydroxymethylene, or methylene; and R.sub.3 is hydrogen or hydroxy; and salts thereof, provided that when R.sub.1 is hydrogen and R.sub.2 is carbonyl, R.sub.3 is not hydroxy, with processes for preparing same and with their use in medicine for the treatment of hypertension.

  本发明涉及公式（I）的化合物##STR1##其中，R.sup.1为氢或C.sub.1-4烷氧基；R.sub.2为羰基，羟甲基或亚甲基；R.sub.3为氢或羟基；以及它们的盐，但当R.sub.1为氢且R.sub.2为羰基时，R.sub.3不是羟基。本发明还涉及制备这些化合物的方法以及它们在医药上治疗高血压的用途。
• Novel therapeutic agents for membrane transporters
  申请人：——

  公开号：US20030044845A1

  公开（公告）日：2003-03-06

  Novel multi-binding compounds (agents) are disclosed which bind cell membrane transporters including ion channels, molecular transporters and ion pumps. The compounds of this invention comprise from 2 to 10 ligands each of which can bind to such cellular transporters to modulate the biological processes/functions thereof. Each of the ligands is covalently attached to a linker (framework) to provide for a multi-binding compound. The linker is selected such that the multi-binding compound exhibits increased modulation of the biological processes/functions of the transporter as compared to the aggregate of the individual ligand units made available for binding to the transporter.

  本发明揭示了一种新型多重结合化合物（试剂），其结合细胞膜转运体，包括离子通道、分子转运体和离子泵。本发明的化合物包括2到10个配体，每个配体都可以结合到这些细胞转运体上，以调节其生物过程/功能。每个配体都共价地连接到一个连接器（框架）上，以提供多重结合化合物。所选择的连接器是为了使多重结合化合物相比可用于结合转运体的单个配体单元的聚合体表现出增强的调节转运体的生物过程/功能的特性。
• Renin inhibitors containing histidine replacements
  申请人：Merck & Co., Inc.

  公开号：EP0273696A2

  公开（公告）日：1988-07-06

  Peptides of the formula: which comprises novel elements replacing the His(9) sequence in renin-inhibitory peptides based on substrate analogy, which have improved bioavailability and pharmacodynamic properties; compositions containing these renin-inhibitory peptides, optionally with other antihypertensive agents; and methods of treating hypertension or congestive heart failure or of establishing renin as a causative factor in these problems employing the novel peptides.

  该文描述了一种新的肽类分子，其公式为：其中替代了肾素抑制肽中亮氨酸（9）序列的新元素，基于底物类比，具有改善的生物利用度和药效学特性；包含这些肾素抑制肽的组合物，可选地与其他降压药物一起使用；以及使用这些新肽治疗高血压或充血性心力衰竭或确定肾素作为这些问题的致因因素的方法。